TY - JOUR
T1 - Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients
AU - Krowinkel, Miranda
AU - Louwers, Yvonne
AU - Mulders, Annemarie
AU - Jong, Frank
AU - Fauser, BCJM
AU - Laven, Joop
PY - 2014
Y1 - 2014
N2 - Objective: To evaluate the influence of oral contraceptive pills (OCPs) on anthromorphometric, endocrine, and metabolic parameters in women with polycystic ovary syndrome (PCOS). Design: Retrospective cross-sectional cohort study for the period 1993-2011. Setting: Tertiary university hospital. Patient(s): PCOS patients, who never, ever, or at time of screening were using OCPs were included. A total of 1,297 patients, of whom 827 were white, were included. All PCOS patients diagnosed according to the Rotterdam 2003 consensus criteria were divided into three groups: current users, (n = 76; 6% of total), ever users (n = 1,018; 78%), and never users (n = 203; 16%). Ever users were subdivided based on the OCP-free interval. Intervention(s): None. Main Outcome Measure(s): Anthromorphometric (blood pressure, cycle duration) and ultrasound (follicle count, mean ovarian volume) parameters, endocrine (SHBG, testosterone, free androgen index, antimullerian hormone [AMH]) and lipid profiles. Result(s): Current users and ever users were compared with never users. In current users, SHBG was increased and androgen levels decreased. Patients with an OCP-free interval of < 1 year had a higher mean follicle count, higher AMH level, and increased serum androgen level compared with never users. SHBG levels remained increased until 5-10 years after cessation of OCP use. Conclusion(s): OCP use causes a milder phenotypic presentation of PCOS regarding hyperandrogenism. However, it does not alter parameters associated with increased health risks. (C) 2014 by American Society for Reproductive Medicine.
AB - Objective: To evaluate the influence of oral contraceptive pills (OCPs) on anthromorphometric, endocrine, and metabolic parameters in women with polycystic ovary syndrome (PCOS). Design: Retrospective cross-sectional cohort study for the period 1993-2011. Setting: Tertiary university hospital. Patient(s): PCOS patients, who never, ever, or at time of screening were using OCPs were included. A total of 1,297 patients, of whom 827 were white, were included. All PCOS patients diagnosed according to the Rotterdam 2003 consensus criteria were divided into three groups: current users, (n = 76; 6% of total), ever users (n = 1,018; 78%), and never users (n = 203; 16%). Ever users were subdivided based on the OCP-free interval. Intervention(s): None. Main Outcome Measure(s): Anthromorphometric (blood pressure, cycle duration) and ultrasound (follicle count, mean ovarian volume) parameters, endocrine (SHBG, testosterone, free androgen index, antimullerian hormone [AMH]) and lipid profiles. Result(s): Current users and ever users were compared with never users. In current users, SHBG was increased and androgen levels decreased. Patients with an OCP-free interval of < 1 year had a higher mean follicle count, higher AMH level, and increased serum androgen level compared with never users. SHBG levels remained increased until 5-10 years after cessation of OCP use. Conclusion(s): OCP use causes a milder phenotypic presentation of PCOS regarding hyperandrogenism. However, it does not alter parameters associated with increased health risks. (C) 2014 by American Society for Reproductive Medicine.
U2 - 10.1016/j.fertnstert.2014.02.039
DO - 10.1016/j.fertnstert.2014.02.039
M3 - Article
C2 - 24680368
SN - 0015-0282
VL - 101
SP - 1757-U344
JO - Fertility & Sterility
JF - Fertility & Sterility
IS - 6
ER -